Gilead
Pharma in 2018: Looking back, looking forward
December 18, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2018, Alligator Bioscience, Eisai, Gilead, Mundipharma, pharma
2018 has been a year characterised by uncertainty, but also significant leaps in research, access, and industry deals. With 2019 …
The December issue of Pharmafocus is available to read online now!
December 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eisai, GSK, Gilead, Mundipharma, Pharmafocus, mesothelioma, pharma
The December edition of Pharmafocus is live and available to read online now!Brexit continues to dominate the headlines inside and …
Gilead names Roche veteran Daniel O’Day as new CEO
December 10, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Gilead, Roche, appointment
Almost half a year since it was revealed that Gilead’s Dr John Milligan would be stepping down from his role …
NICE give go-ahead to Gilead’s Yescarta for adults with lymphoma
December 7, 2018Medical Communications Cancer, Cost, Gilead, NHS, NICE, Yescarta, access
The NHS cost effectiveness body NICE has approved Gilead’s Yescarta for treatment of come adults with lymphoma. Gilead’s treatment will …
Gilead’s CAR-T therapy Yescarta shows two-year response duration in large B-cell lymphoma
December 3, 2018Research and Development, Sales and Marketing ASH 2-18, CAR-T, Cancer, Gilead, Yescarta, leukaemia, pharma
Gilead has gone head to head with Novartis at the American Society of Hematology (ASH) Annual Meeting 2018, meeting the …
NHS England appoves Gilead’s CAR T therapy Yescarta
October 5, 2018Medical Communications Gilead, NHS, NICE, UK, Yescarta
Gilead’s CAR T therapy Yescarta is set to be made available on the NHS in England for adults with aggressive …
Gilead to release generic versions of hep C meds over a decade before patent expiry
September 28, 2018Medical Communications, Sales and Marketing Epclusa, Gilead, generics, harvoni, hepatitis C, pharma
Gilead has announced its intention to undercut itself by releasing generic versions of its blockbuster drugs for the treatment of …
Gilead and Galapagos’ ankylosing spondylitis drug hits Phase 2 trial goal
September 7, 2018Medical Communications, Research and Development Galapagos, Gilead, ankylosing spondylitis, filgotinib, pharma
Gilead and Galapagos have announced that their jointly-developed selective JAK1 inhibitor filgotinib has met its primary endpoint in a Phase …
Novartis’ CAR T therapy Kymriah to become available on the NHS
September 5, 2018Research and Development CAR T, CAR-T, Gilead, Kymriah, NHS, Novartis
Novartis’ Kymriah is set to become the first CAR T therapy to become available on the NHS after it was …
Novartis’ Kymriah & Gilead’s Yescarta become first EU-approved CAR T therapies
August 28, 2018Manufacturing and Production, Sales and Marketing CAR T, CAR-T, Cancer, EU, Gilead, Kymriah, Novartis, UK, Yescarta, blood cancer, pharma
Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah …
Gilead CMO announces departure alongside two new exec appointments
August 17, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, pharma
Gilead has announced that its Chief Medical Officer is to vacate the role after just five months and leave the …
Gilead CMO announces departure alongside two new exec appointments
August 15, 2018Medical Communications, Research and Development Gilead, pharma
Gilead has announced that its Chief Medical Officer is to vacate the role after just five months and leave the …
Gilead’s CEO and Chairman to both step down before year’s end
July 30, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, pharma
Gilead has announced that its President and Chief Executive Officer Dr John Milligan (pictured) will be stepping down by the …
Top Ten most popular articles on Pharmafile.com this week
July 27, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, China, GSK, Gilead, J&J, JJ, Pfizer, Remicade, Roche, antimicrobial resistance, biosimilar, pharma, pricing, viagra
With the UK in the grip of a record-breaking heatwave, it’s hard to focus on much else over here, but …
Gilead’s CEO and Chairman to both step down before year’s end
July 26, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, pharma
Gilead has announced that its President and Chief Executive Officer Dr John Milligan (pictured) will be stepping down by the …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
